GLP-1, or {glucagon-like|glucagon like|glucagon) peptide-1, is currently emerging as a major focus in healthcare studies, largely due to its impressive impact on controlling ailments such as type 2 diabetes and excess body fat. Ongoing studies have demonstrated that more than glucose control, GLP-1 agonists offer benefits for circulatory health and